Novartis has announced encouraging results from two pivotal studies involving its experimental drug, ianalumab, targeting two different autoimmune indications. As reported by BioPharma Dive, the Swiss pharmaceutical company revealed positive data from two Phase 3 trials in primary Sjögren’s syndrome and another Phase 3 trial in a rare autoimmune disease, primary immune thrombocytopenia (ITP), underscoring ianalumab’s potential as a versatile therapy.

Breakthrough in Sjögren’s Syndrome

Primary Sjögren’s syndrome is a chronic autoimmune disorder marked by the body’s immune system attacking moisture-producing glands, leading to dry mouth, dry eyes, fatigue, and joint pain. With limited treatment options and no currently approved disease-modifying therapies, there is a significant unmet need for patients.

Novartis’ topline data readouts of two Phase 3 trials found that ianalumab met its primary endpoint in both trials, significantly reducing disease activity compared to placebo. The trial’s success suggests that ianalumab could become the first approved therapy directly targeting the underlying disease mechanism in Sjögren’s syndrome, not just its symptoms. Ianalumab works by targeting the BAFF receptor on B cells, cells that play a key role in autoimmune processes. By inhibiting this receptor, the drug helps reduce harmful immune activity without broadly suppressing the immune system.

Positive Results in ITP

In addition, ianalumab was also evaluated in a Phase 3 trial involving patients with ITP, a rare autoimmune disorder in which the immune system mistakenly targets and destroys platelets, the cells essential for blood clotting. The results, showed that ianalumab helped control disease progression in individuals who had previously received treatment, addressing a patient population with limited options.

While detailed data have not yet been published, Novartis expressed optimism about the findings, with plans to share full study results at an upcoming medical meeting and discuss regulatory steps with health authorities.

Implications and Next Steps

The twin successes for ianalumab highlight its potential to serve as a new therapy across multiple autoimmune disorders. Novartis is preparing to engage with regulators on the path to approval for Sjögren’s syndrome, which could bring the first disease-modifying therapy to patients suffering from this chronic condition. In the ITP space, ianalumab could answer a need for new treatment options with novel mechanisms of action that offer reduce the burden of long-term treatment.

Conclusion

Novartis’ ianalumab is emerging as a promising candidate in the treatment of both primary Sjögren’s syndrome and ITP. The positive study results signal hope for patients with limited therapeutic choices and demonstrate the expanding role of targeted therapies in addressing complex diseases. As Novartis advances ianalumab through regulatory discussions, the medical community will watch closely for its potential to change standards of care in both autoimmune diseases.